Astrazeneca PLC insider trades: Viela Bio (VIE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Astrazeneca PLC reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 7, 2019 | VIE | ↑ Buy | 425,000 | $19.00 | $8.1M | Indirect | Oct 9, 2019 (2d) |
| Oct 22, 2018 | PHAS | ↑ Buy | 600,000 | $5.00 | $3.0M | By Zeneca, Inc. | Oct 24, 2018 (2d) |
| Sep 28, 2018 | ETTX | ↑ Buy | 246,666 | $15.00 | $3.7M | Indirect | Oct 2, 2018 (4d) |
| Dec 1, 2017 | ALBO | ↓ Sell | 500,000 | $21.40 | $10.7M | Held by AstraZeneca AB | Dec 5, 2017 (4d) |
| Nov 12, 2014 | RGLS | ↓ Sell | 2,000,000 | $17.00 | $34.0M | Indirect | Nov 14, 2014 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Astrazeneca PLC's insider trades
Astrazeneca PLC is a 10% owner of Viela Bio (VIE). Since Nov 12, 2014, it has reported 3 open-market purchases worth $14.8M and 2 sales worth $44.7M on SEC Form 4. There have been no open-market trades in the last 12 months.
Its filings also include conversions (3 filings), other transactions (2 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VIE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.